<DOC>
	<DOCNO>NCT02560610</DOCNO>
	<brief_summary>The aim study effect OC000459 eosinophilic airway inflammation asthma control subject severe , refractory eosinophilic asthma .</brief_summary>
	<brief_title>Effect OC000459 Eosinophilic Airway Inflammation Severe Asthma</brief_title>
	<detailed_description>At week 12 subject oral corticosteroid ( OCS ) complete treatment period return 4 week final follow visit . Those subject take OCS baseline continue maximum 12 additional week , double blind period current OCS treatment titrate accord clinical response .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Pulmonary Eosinophilia</mesh_term>
	<mesh_term>Indoleacetic Acids</mesh_term>
	<criteria>Show evidence reversible airflow obstruction document within previous 12 month prior Randomisation . Meet European Respiratory Society/American Thoracic Society ( ERS/ATS ) criterion severe asthma Screening . Have document evidence eosinophilic airway inflammation 12 month prior Screening . Have evidence eosinophilic airway inflammation Screening reflect induced sputum eosinophil count â‰¥3 % . Subjects take oral corticosteroid ( OCS ) must receive 20 mg prednisolone equivalent dose , less , daily least four week first dose study drug . The dose OCS unchanged least 14 day prior Baseline visit . Treatment XolairTM antiTh2 biologicals within 6 month prior screen . Subjects clinically significant abnormal serum biochemistry , haematology urine examination value Subjects hospitalise last 3 month . History 2 episode confirm bacterial low respiratory tract infection current low respiratory tract infection . Subjects current smoker smoke history &gt; 15 pack year . Significant comorbidity Investigator 's opinion likely impact subject 's participation 26 week study . Presence clinically important lung condition asthma , malignancy previous history cancer remission le 12 month , clinically important liver kidney disease , uncontrolled clinically significant cardiovascular disease , hypereosinophilic syndrome ChurgStrauss Syndrome eosinophilic oesophagitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>